Stay updated on AFM24 + Atezolizumab in EGFR+ Cancers Clinical Trial
Sign up to get notified when there's something new on the AFM24 + Atezolizumab in EGFR+ Cancers Clinical Trial page.

Latest updates to the AFM24 + Atezolizumab in EGFR+ Cancers Clinical Trial page
- Check3 days agoChange DetectedThe page now displays Revision: v3.0.2, replacing Revision: v3.0.1. The Back to Top element has been removed.SummaryDifference0.2%
- Check10 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.2%
- Check17 days agoChange DetectedThe web page has undergone significant updates, including the addition of specific facility names and locations in South Korea and Poland, as well as new content related to drug administration and therapy. Notably, the version has been updated from v2.16.12 to v3.0.0.SummaryDifference8%
- Check24 days agoChange DetectedThe study assessing AFM24 in combination with Atezolizumab has been terminated due to financial issues, and several key dates and metrics related to the study have been updated or removed.SummaryDifference49%
- Check31 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.1%
- Check39 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11.SummaryDifference0.1%
Stay in the know with updates to AFM24 + Atezolizumab in EGFR+ Cancers Clinical Trial
Enter your email address, and we'll notify you when there's something new on the AFM24 + Atezolizumab in EGFR+ Cancers Clinical Trial page.